☆ 4.6 Article

Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma

BLOOD ADVANCES (2023)

Related references

Note: Only part of the references are listed.

Article Hematology

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

Mi Kwon et al.

Summary: This retrospective study evaluated the safety and efficacy of Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) in relapsed/refractory large B-cell lymphoma (LBCL) outside of clinical trials. The results showed that the real-world experience with these CAR-T cell therapies was comparable to the pivotal trial results.

HAEMATOLOGICA (2023)

Add to Collection

Letter Oncology

Prognostic value of FDG-PET/CT response for patient selection before chimeric antigen receptor-T-cells therapy in non-Hodgkin lymphoma

Clement Bailly et al.

HEMATOLOGICAL ONCOLOGY (2022)

Add to Collection

Letter Hematology

Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma

Andrea Kuhnl et al.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma

Ann-Marie E. Broeske et al.

Summary: This study evaluated the clinical activity of a novel antibody called glofitamab in relapsed/refractory B-cell non-Hodgkin lymphoma patients and provided evidence of its pharmacodynamic profile, mode of action, and factors associated with clinical response by evaluating biomarkers. The results showed that glofitamab can activate T cells, inhibit tumor cells, and is associated with certain tumor characteristics.

BLOOD ADVANCES (2022)

Add to Collection

Article Oncology

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

Kai Rejeski et al.

Summary: The study demonstrates the utility of the HT score for risk-stratifying patients for infectious complications and poor survival outcomes prior to CD19 CAR-T therapy. High-risk patients may benefit from anti-infective prophylaxis and close monitoring for potential infections and relapse. Patients with high HT scores are more likely to develop severe infections, which represent a common cause of non-relapse mortality after CAR-T.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Biochemistry & Molecular Biology

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Emmanuel Bachy et al.

Summary: This study compared the efficacy and toxicity of Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL). The results showed that axi-cel had better overall response rate, complete response rate, progression-free survival, and overall survival compared to tisa-cel. However, axi-cel also had higher frequency of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome compared to tisa-cel.

NATURE MEDICINE (2022)

Add to Collection

Article Hematology

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Kitsada Wudhikarn et al.

Summary: CD19-targeted CAR T-cell therapy is a breakthrough treatment for relapsed/refractory B-ALL patients, but most adult patients progress after treatment. Although some patients achieve sustained remissions with salvage treatments such as blinatumomab, inotuzumab, and reinfusion of CAR T cells, the overall prognosis remains poor. Novel therapeutic strategies are needed to reduce the risk of progression and improve outcomes for these patients.

BLOOD (2021)

Add to Collection

Article Hematology

CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Kai Rejeski et al.

Summary: Hematotoxicity is a common adverse event in CAR T-cell therapy, with baseline thrombocytopenia and hyperferritinemia being significant predictive markers. The CAR-HEMATOTOX model can accurately predict the occurrence of severe neutropenia.

BLOOD (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells

Pierre Sesques et al.

Summary: The study found that metabolic volume kinetics before CAR T-cell infusion is superior in predicting progression-free survival (PFS), while SUVmax at M1 can effectively segregate patients with different prognosis for overall survival (OS).

CLINICAL NUCLEAR MEDICINE (2021)

Add to Collection

Article Oncology

Bispecific antibodies for the treatment of lymphomas: Promises and challenges

Stephen J. Schuster

Summary: Bispecific antibodies can redirect T cell-mediated cytotoxicity towards tumor cells by combining T-cell receptor-specific monoclonal antibodies with tumor-targeting antibodies, thereby focusing cytotoxic effects on tumor cells independently of T-cell receptor specificity. Early results from phase 1 clinical trials targeting CD20 on B cells and engaging T cells via CD3 have shown promising potential for treating relapsed or refractory B-cell lymphomas.

HEMATOLOGICAL ONCOLOGY (2021)

Add to Collection

Article Hematology

FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR‐T CELLS AND ENROLLED IN DESCAR‐T REGISTRY, A FRENCH REAL‐LIFE DATABASE FOR CAR‐T CELLS IN HEMATOLOGIC MALIGNANCIES

S. Gouill et al.

HEMATOLOGICAL ONCOLOGY (2021)

Add to Collection

Article Hematology

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Nora Liebers et al.

Summary: The antibody-drug conjugate polatuzumab vedotin (pola) in combination with bendamustine and rituximab (pola-BR) has shown efficacy for patients with refractory or relapsed large B-cell lymphoma in a real-world setting. The treatment achieved encouraging overall response rates in salvage therapy and successfully bridged a significant number of patients to CAR T-cell therapy. These findings suggest that pola may serve as an effective salvage and bridging treatment option for patients with refractory or relapsed LBCL.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Ibrahim Yakoub-Agha et al.

HAEMATOLOGICA (2020)

Add to Collection

Article Oncology

Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma

Christopher M. Wright et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)

Add to Collection

Article Oncology

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Loretta J. Nastoupil et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Hematology

Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma

Chelsea C. Pinnix et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Medicine, General & Internal

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson et al.

LANCET (2020)

Add to Collection

Article Hematology

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL

Andre Goy et al.

BLOOD (2019)

Add to Collection

Article Hematology

REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE PROGRAM

C. Thieblemont et al.

HEMATOLOGICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma

Austin J. Sim et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)

Add to Collection

Meeting Abstract Hematology

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Samantha Jaglowski et al.

BLOOD (2019)

Add to Collection

Meeting Abstract Hematology

Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Michael D. Jain et al.

BLOOD (2019)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Hematology

Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion

Michael R. Bishop et al.

BLOOD ADVANCES (2019)

Add to Collection

Meeting Abstract Hematology

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience

Loretta J. Nastoupil et al.

BLOOD (2018)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

© Peeref 2019-2024. All rights reserved.